category,datetime,headline,id,image,related,source,summary,url
company,1768057200,RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer,138068893,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,"Johnson & Johnson (NYSE:JNJ) today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. The encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further",https://finnhub.io/api/news?id=46dd3f2403677e9b9a640bff05385dcdc8c3f4a141b6c609a547808300e7f40c
company,1768053576,The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth,138068856,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,"Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady",https://finnhub.io/api/news?id=8b1d9c99be103cbc679e34b532ea70b12e59e54f629b773f57c72a0403ed1f73
company,1768038721,January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy,138055995,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1839458057/image_1839458057.jpg?io=getty-c-w1536,JNJ,SeekingAlpha,January 2026 Dogs of the Dow update: Verizon is the only âdogcatcherâ stock.,https://finnhub.io/api/news?id=1660b2a2ba8c3d9e6bd7a573907b58ceded4a1a0c4d63c9ba3a114cc975bf4d3
